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SUMMARY
We investigated the in vivo effect of recotnbinant interferon-y (IFN-7) and tumour necrosis
factor y. (TNF-a) treatment of mice on the development of the delayed-type hypersensitivity
(DTH) reaction and hchenoid tissue reaction (LTR) following the local injection of cloned
autorcactive T cells. Both the DTH reaction and the LTR were significantly enhanced by pre-
treatment with IFN-y, but not with TNF-a. Induction of class II MHC antigens on
keratinocytes was not essential for the enhancement by IFN-7. Administration of anti-IFN-y
antibody reduced the DTH reaction and LTR, although complete inhibition was not observed
with our treatment regimen. The ability of IFN-y to increase the number of the cloned T cells
invading the epidertnis in vivo, is in keeping with our previous observation that IFN-y treatment
of cultured keratinocytes markedly increased the adherence reaction between T cells and
keratinocytes in vitro.
Interferon-y (IFN-y) is a lymphokine produced by T cells upon activation by an antigen or
mitogen. In addition to its antiviral and antiproUferative activities,' IFN-y has a number of
effects which favour the development of infiammation: it induces the expression of class II
major histocompatibility complex (MHC) antigens on normally negative cells including
keratinocytes,^ enhances lymphocyte adhesion molecule expression by monocytes,"' functions
as a macrophagc-activating factor,* and augments the phagocytic and cytotoxic activities of
neutrophils.^ Aberrant expression of class II MHC antigens on normally negative cells in a
variety of autoimmune diseases*" and the modulation of this expression by IFN-y^ raise the
intriguing possibility that unregulated production of IFN-y may be central to the development
of autoimmunity.^
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We have recently demonstrated that murine autoreactive cloned T cells capable of producing
IFN-7 and tumour necrosis factor (i (TNF-/6) evoke the cutaneous delayed-type hypersensiti-
vity (DTH) reaction and lichenoid tissue reaction (LTR) upon intradermal inoculation into
normal syngeneic hosts.** The LTR evoked by these T cells was most probably mediated by a
synergistic effect between IFN-7 and TNF-// released from the T cells in situ.^''° Since IFN-y
has been observed to greatly enhance the adherence reaction between T cells and cultured
keratinocytes in vitro,^^ we investigated the possibility of an in vivo counterpart of this reaction.
These findings led us to investigate the in vivo effect of recombinant IFN-y and anti-IFN-y
antibody on the development of the lichenoid tissue reaction.
METHODS
Animals
Female C57BL/6 (B6) mice were obtained from Charles River Japan, Inc. and maintained in our
animal facility. They were used predominantly at 8 to 12 weeks of age.
Induction of the lichenoid tissue reaction
Two different kinds of autoreactive cloned T cells specific for class II MHC antigens, I-A^, were
established in previous experiments.'*'"^ BB5 cells, when injected into the footpads of syngeneic
B6 mice, migrate into the epidermis and cause the destruction of the epidermal cells." Cio cells,
in contrast, are completely incapable of migrating into the epidermis and consequently fail to
induce the epidermal change.^
Assay for the delayed type hypersensitivity reaction
The cloned T cells were harvested from culture 7-8 days after antigenic stimulation. The T cells
with a viability greater than 95*̂ 0 were injected intradermally, at different doses and in a volume
of 25 ^1, into the hind footpads of B6 mice. The resultant swelling of the footpads was measured
with a dial thickness gauge 48 h after injection, as described previously.^
Evaluation of the lichenoid tissue reaction
At 72 h after injection of the T cells, skin samples from the hind footpads of the mice were
excised using scissors, fixed in 37",, buffered formaldehyde, embedded in paraffin, sectioned,
and stained with haematoxylin and eosin. The LTR was defined as the intensity of epidermal
invasion by the injected T cells as follows. A semi-quantitative evaluation of epidermal invasion
by the injected T cells was performed by counting lymphoid cells within the epidermis. At least
30 serial sections from each individual footpad were examined, and of these the six sections in
which the epidermis was regarded to be most heavily infiltrated with lymphoid cells were
counted. The results were expressed as the number of lymphoid cells per linear mm of
epidermis, as previously described.^
Reagents
Recombinant mouse IFN-y (098 mg/ml; specific activity: 23 x io** U/ml), purified rabbit
antibody against mouse IF^J-y (i 2 mg/ml; i ml of antibody neutralizes i 28 x 10̂  U of IFN-y)
and recombinant human TNF-a (050 mg/ml; specific activity; 251 x 10̂  U/ml) were a gift
from Dr. H.M.Shepard (Genetech, Inc., South San Francisco, CA, U.S.A.). They were stored
at 4 C and diluted in phosphate-buffered saline (PBS) before use. IFN-y or TNF-a was injected
intradermally into the hind footpads ofB6 mice on 2 or 6 successive days at a dose of 05-5 x 10*
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U/day. Control mice received the corresponding quantities of PBS alone. In some experiments,
on days o and i or i and 2, anti-IFN-y antibody (50 /il) was injected into the same footpad site
that had received BB5 cells on day o. In these experiments, control mice received 50 /xl PBS
containing 60 jj.g of chromatographically purified rabbit IgG (Cappel Laboratories, Cochville,
PA, U.S.A.)- Because no significant changes were observed between mice injected with PBS
alone and those injected with rabbit IgG-containing PBS, with respect to footpad swelling and
histology, the latter mice were used as the proper controls in these experiments.
RESULTS
Local administration of IFN-y enhanced the D TH reaction and lichenoid tissue reaction induced by
the autoreactive T cells
To elucidate the effect of IFN-y in-vivo on the DTH reaction and LTR induced by the local
transfer of the autoreactive T cells, groups of normal B6 mice were pre-treated by the
intradermal injection with 0-5 x 10* U of either IFN-y or TNF-a on the two days preceeding
injection of the T cells. This dose of IFN-7 or TNF-a was selected because in the absence of
added autoreactive T cells, it has been found not to evoke significant pathological changes. On
day o, I X 10̂  BB5 cells were injected into the same site that had been injected with IFN-y,
TNF-a or PBS. As shown in Table i and Fig. i, pre-treatment with IFN-y significantly
enhanced the epidermal invasion by BB5 cells and, to a lesser extent, the DTH reaction, while
the effect of TNF-a in vivo was slight. When BB5 cells were given at a lower dose (o- 5 x 10̂  cells/
mouse), the enhancement was more pronounced. Moreover, concomitant injection of anti-
IFN-y antibody with IFN-y abrogated its ability to enhance the DTH reaction and LTR
induced by BB5 cells. However, when IFN-y was injected after the injection of BB5 cells, the
enhancement was found to be minimal. Compared with treatment with IFN-y alone, no
augmentation was observed after simultaneous treatment with IFN-y and TNF-a. We then
TABLE I. Ability of IFN-y to enhance rhe DTH reaction and LTR
No. of T cells
injected
Experiment i
1 X IO" BBS
I X IO" BB5
I X 10" BB5
I X 10** C I O
I X 10^ C I O
Experiment 2
0-5 X 10" BB5
0-5 X 10" BB5
O-5 X lo*" BB5
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Values are means ± SD of 3-4 mice.
Significantly differem from control; *P<005, **/'<0-0O5 (Student's i-test).
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FIGURE I. Epidermal invasion of BBs cells 72 h after injection of i x 10" cells into the footpads of
syngeneic mice who had been injected at the same site on the 2 preceeding days with (a) IFN-v
O'5 X io*U or (b) PBS. (H&F; original x 120).
investigated whether local administration of IFN-y could induce a non-epidermotropic clone,
CIO, to migrate into the epidermis. In contrast to the enhanced migration of BB5 cells, Cio cells
were still incapable of migrating into the epidermis after in vivo treatment with IFN-y, although
the DTH reaction was similarly enhanced.
The ability of IFN-y to enhance the DTH responses and LTR is not mediated through the induction
of I-A antigens by keratinocytes
It has been suggested that the expression of I-A (class II MHC antigens in mice) by
keratinocytes may help direct the migration of lymphocytes into the skin during DTH
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Values are means ± SD of 4 mice.
Significantly diflFerent from control; */ '<o 05, **P< 0 005 (Student's i-test).
responses. ̂ ^ We, therefore, tested whether the ability of IFN-7 to induce keratinocytes to
express I-A antigens was involved in the observed enhancement of the DTH reaction and LTR
by IFN-y. However, after in vivo treatment with o- 5 x i o'* U IFN-y for 2 days, the epidermis did
not show intercellular staining for I-A antigens, as judged by indirect immunofluorescence
staining of frozen sections of footpad skin. The induction of I-A antigens on keratinocytes was
found to be obtained with 5 x 10* U IFN-v given on 6 consecutive days (data not shown). The
repeated intradermal injections with this dose of IFN-y were, however, usually associated with a
signiflcant increase in dermal infiltrates, that were not observed in mice injected with 05 x 10''̂
U IFN-y on 2 consecutive days. However, no intra-epidcrmal lymphoid cells were observed in
mice that had received 5 x 10* IFN-y for 6 days, but not followed by the injection of BB5 cells.
As shown in Table 2, 6 days of treatment with higher doses (5 x io'* U) of IFN-y markedly
enhanced the DTH reaction and LTR. These results suggest that the enhancement by IFN-y
could be dose-dependent, although we cannot exclude the possibility that the higher dose of
IFN-y would have resulted in endogenous IFN-y production by host lymphocytes, thus
contributing to some of the observed enhancement.
Treatment with anti-IFN-y antibody reduced the DTH reaction and LTR
In order to test whether anti-IFN-y antibody could prevent the development of the LTR, mice
that had received i x 10'' BB5 cells were given intradermal injections with anti-IFN-y antibody
(50 /il). Preliminary studies indicated that treatment of normal mice with this dose of anti-IFN-y
antibody elicited neither significant dermal infiltration, nor footpad swelling. As shown in Table
3, administration of anti-IFN-y antibody signiflcantly reduced the DTH reaction and
epidermal invasion by BB5 cells when the administration was delayed to day i after injection of
BB5 cells. In contrast, prevention of the DTH reaction and LTR by anti-IFN-y antibody was
not observed when mice were injected with the antibody immediately after the injection of BB5
cells. The degree of inhibition by anti-IFN-y antibody was more profound in the DTH reaction
than in the LTR. However, two intradermal injections of anti-IFN-y antibody at 24 h intervals
did not completely abrogate the capacity of BB5 cells to elicit the DTH reaction and LTR.
DISCUSSION
To clarify the role of IFN-y in the pathogenesis of the lichenoid tissue reaction, we treated mice
with repeated injections of recombinant mouse IFN-y before the local injection of cloned T cells
capable of inducing the LTR. The treatment enhanced the DTH reaction and the LTR induced
by the T cells. This enhancement appeared not to be due to the induction of I-A antigens on
204 T.Shiohara et al.















r J i_ • 1
toot pa a thickness




































Values are means ± SD of 3-4 mice.
Significantly different from control; */'<o-oi, **P<OQOf, (Student's t-test)
ND = not done.
keratinocytes by IFN-y, because I-A antigen expression on keratinocytes was never observed in
footpads injected with the lower dose of IFN-y on 2 consecutive days, where both the DTH
reaction and LTR were significantly enhanced. It has been proposed that in the LTR, IFN-y
secreted by activated lymphocytes in the upper dermis could induce basal keratinocytes to
express class II MHC antigens in a wide variety of dermatoses' ̂  and that I-A antigen expression
by keratinocytes may pennit them to function as antigen-presenting cells, like Langerhans
cells. ̂ "̂  However, experimental evidence has recently been presented to challenge such a
hypothesis. Gaspari et al}^ have shown that class II antigen positive keratinocytes do not
replace Langerhans cells in their capacity to induce various immune responses. Our present
finding also argues against the critical role of class II antigen positive keratinocytes in the
induction of the LTR, although our failure to detect I-A antigens on keratinocytes after
treatment with the lower dose of IFN-y does not necessarily exclude their presence, or their
appearance later and possible significance in perpetuating the inflammatory response.
What, then, is the mechanism by which IFN-y enhances the DTH reaction and LTR? IFN-y
has been shown to induce synthesis of TNF receptors in some cells and thereby increase their
sensitivity to the cytostatic activity of TNF. "̂  It is, therefore, possible that exogenous IFN-y
may act to increase TNF receptors on keratinocytes, thereby rendering them more sensitive to
TNF released from activated T cells and macrophages. In addition, IFN-y preferentially
enhances the interleukin 1 (IL-i) secretory potential of monocytes.'^ Because epidermal cell-
derived thymocyte-activating factor (ETAF)/IL-i has been reported to be a potent chemo-
attractant for T cells,'^ IFN-ymay act to enhance the migration of T cells into the epidermis,
through its capacity to stimulate keratinocytes to release ETAF.
With respect to a role for IFN-y in promoting T cell adhesion to keratinocytes, we have
recently observed that IFN-y-treated keratinocytes display a markedly increased adherence
reaction towards monocytes and T lymphocytes."'' ̂  This adherence reaction did not appear to
involve class II antigens, as antibody to this antigen did not inhibit the reaction, but antibody
against lymphocyte function-associated antigen i (LFA-i) totally blocked the binding. Thus, it
is possible that IFN-}- increased the number of BB5 cells in the epidermis by promoting the
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adherence reaction between lympbocytes and keratinocytes in vivo as we bave previously
observed in vitro. In fact, the kinetics of the reaction in vivo agree well with our in vitro
observations'* in which significant enhancement of binding by IFN-y was seen between i and 2
days. Wben we compared IFN-y to TNF-a in the in vitro adherence assay, IFN-y was better
tban TNF, and the failure to observe significant changes witb TNF-ct in tbe present in vivo
study may refiect the requirement for higher concentrations of TNF-a to be used than could be
achieved in tbe present study.
It has been shown that TNF-a and -^, secreted by macrophages and lymphocytes,
respectively, share several activities with IFN-y, including cytotoxic or cytostatic effectŝ *̂  and
ability to enhance the expression of a family of leukocyte adhesion molecules.^' Moreover, the
synergistic effect of the two lymphokines is frequently observed^^ and most IFN-y-producing
T cells as well as our cloned T cells can also release TNF-/{ (N.H. Ruddle, personal
communication).^^ It is possible, therefore, that the two lympbokines could exist in
combination, but not in isolation, in the physiological environment. However, the apparent
incapacity of TNF-a to enhance the LTR and to act synergistically with IFN-y suggests tbat tbe
enhancement of the LTR may be a property unique to IFN-y, Alternatively, because TNF
treatment has been reported to result in synthesis of prostaglandins,^* the capacity of TNF-a to
enhance the DTH reaction and the LTR may have been abrogated through tbe generation of
prostaglandins, which has been shown to suppress cell-mediated immune responses including
DTH reactions.
In the light of the crucial role of IFN-y in the patbogenesis of the LTR, administration of
anti-IFN-y antibody might constitute an effective strategy for the treatment of various lichenoid
skin diseases. Our results show that although partial prevention of the LTR was achieved by
treatment with anti-IFN-y antibody, the reduction was less pronounced than expected from the
in vivo enhancing effect of IFN-y. Tbe reason why the DTH reaction and LTR were not
completely abrogated by anti-IFN-y antibody treatment is not clear, but might have simply
been due to use of anti-IFN-y antibody at insufficient concentrations, or failure to maintain
effective concentrations for a sufficiently long period to neutralize IFN-y released from
activated T cells in situ. Thus, it remains to be determined whether treatment witb anti-IFN-y
antibody could be a useful therapeutic approach to LTR and other autoimmune diseases, as is
the case with antibodies to T cell surface molecules.^^
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